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Background: Enumeration of circulating tumor cells (CTCs) may
be valuable for lung cancer treatment and monitoring cancer patient
relapse. In the present study we report clinical significance of lung
cancer CTC.
Methods: CTCs were enriched from peripheral blood of 47 lung
cancer patients by means of a modified enrichment strategy, fol-
lowed by identification with immunofluorescence staining using
anticytokeratins 18 and 19 monoclonal antibodies.
Results: A control group consisted of 18 healthy donors and 13
nonmalignant pulmonary tuberculosis patients had no positive sub-
ject detected. Among 41 newly diagnosed and 6 recurrent lung
cancer patients (3 stage I–II, 22 stage III and 22 stage IV) including
27 adenocarcinoma (ADC), 7 squamous cell carcinoma and 13 small
cell lung cancer (SCLC), positive detection rate of newly diagnosed
patients with CTC 2/7.5 ml blood was 78% (ADC stage III), 75%
(squamous cell carcinoma stage III) and 60% (SCLC stage III),
respectively. Whereas 46% (ADC IV) and 71% (SCLC IV) were
observed for stage IV patients. Recurrent patients showed highest
detection sensitivity of 83%. A small scale follow-up study was
performed on 12 patients following 2 courses of first line chemo-
therapy. This demonstrated a good correlation of CTC enumeration
with radiographic response.
Conclusions: Results of the present study suggest potential clinical
utilities of CTC enumeration on lung cancer patients in terms of
rapid evaluation of chemotherapy effect in real time and monitoring
lung cancer recurrence. A large scale of study which is necessary for
further validation of the significance of lung cancer CTC is being
performed.
Key Words: Circulating tumor cell (CTC), Lung cancer, Enrich-
ment, CT, Chemotherapy.
(J Thorac Oncol. 2009;4: 30–36)
Lung cancer is the leading cancer of all cancer-related deathin most countries. Roughly 20% are from small cell lung
cancer (SCLC), and 80% are non-small cell lung cancer
(NSCLC) which includes adenocarcinoma (ADC) and squa-
mous cell carcinoma (SCC).1 Worldwide, 5-year survival rate
of lung cancer patient is less than 5 to 15%2 Nearly 50% of
early-stage lung cancer patients will relapse or develop me-
tastases within 5 years after surgical removal of tumor mass,
indicating the existence of occult metastatic cells which can
not be effectively detected by current methods.
Circulating tumor cells (CTCs) are tumor cells shed
from the primary tumor into blood circulation. Though some
people debate the biologic significance of CTC due to tumor
genomic instability and potential metastatic inefficiency,3 the
implication of CTC in metastasis,4,5 prognosis and predicting
progression-free and overall survival1,6–8 etc. from many
studies have been described elsewhere. In addition, clinical
significance of molecular characterization of the mutated
epidermal growth factor receptor gene on CTC in NSCLC
patients with respect to predicting chemotherapy response has
been recently reported as well.9 In view of its obvious clinical
relevance, CTC has been recently recommended by the
American Society of Clinical Oncology as an acceptable
breast cancer (BCA) marker.10
Although various methods,11,12 including chip technol-
ogy,13 filtration, immunoparticle isolation, flow cytometry,14
reverse transcription-polymerase chain reaction,15,16 and flu-
orescence in situ hybridization 17 have been developed and
employed in an attempt to detect CTC in peripheral blood, the
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approach for detecting lung cancer CTC still needs to be
improved in terms of sensitivity and specificity.13,18
The purpose of the present study was to validate a new
CTC enrichment strategy on the peripheral blood from lung
cancer patients and to perform a preliminary study to inves-
tigate clinical significance of lung cancer CTC. The approach
applied in this study for lung cancer CTC detection showed
both high sensitivity and specificity. In addition, a good
correlation of CTC with radiographic response to chemother-
apy was demonstrated in a follow-up study.
PATIENTS AND METHODS
Enrichment and Identification of CTC from
Peripheral Blood
Enrichment of CTC
The Cytelligen method is essentially similar to that
previously published by others with some modifications.19
Seven and half ml of peripheral blood collected in BD
Vacutainer tube (Becton, Dickinson and a Company, Frank-
lin, NJ) were washed with phosphate buffered saline (PBS)
once, followed by lysis of red blood cell (RBC). The reaction
mixture was spun down at 300g for 5 minutes. Resulting cell
pellet was resuspended in PBS and subsequently incubated
with 0.5 ml of antileukocyte surface marker CD45 monoclo-
nal antibody coated magnetic beads for 30 minutes, followed
by separation of magnetic beads using a magnetic stand
(Promega, Madison, WI). Supernatants were transferred into
a centrifuge tube followed by spinning at 500g for 3 minutes.
Cell pellet was resuspended, and subsequently subjected to
immunofluorescence analysis.
Immunostaining and identification of enriched
CTC
Identification of CTC by means of Cytelligen immuno-
staining approach was performed essentially according to the
protocol previously published with some modifications.20–22
Briefly, cells fixed by 2% paraformaldehyde on slides were
permeabilized with 0.1% Triton X-100, followed by incuba-
tion with monoclonal antibodies anticytokeratin 18 conju-
gated to Alexa Flora 594 (Invitrogen, Carlsbad, CA) and
anticytokeratin 19 conjugated to Alexa Flora 488 for 1 hour.
Sample was washed three times with PBS, followed by
mounting with 4-6-diamidino-2-phenylindole (DAPI) (In-
vitrogen, Carlsbad, CA) containing mounting media, and
subsequently subjected to image analysis using a three-color
fluorescence microscope. The leukocytes marker CD45 was
stained with immunohistochemical staining. Each positive
CTC has to meet following criteria: cell size4 m, cells are
intact with round to oval morphology with visible DAPI
stained nucleus, and positive for both anticytokeratin 18 and
19 staining.
Spiking Study
A validation study was performed to establish the
accuracy of the method to detect cancer cells in blood. Live
human lung cancer cells A549 were labeled with DAPI for 1
hour. Cells were counted with a microscope or were serially
diluted to provide, 5, 10. 20, 50, and 100 cells respectively
and each sample were placed into 7.5 ml blood. This was
followed by the enrichment isolation procedure. Recovered
cancer cells were enumerated using a fluorescent microscope
by a blinded observer. The experiment was repeated in
triplicate for each number of cancer cells, and the total
spiking study was repeated four times.
Patients and Specimens
Consent forms signed by all human subjects including
lung cancer and nonmalignant pulmonary tuberculosis pa-
tients recruited in this study were approved by the Ethics
Review Committee of Peking Union Medical College Hos-
pital. Healthy donors were selected from the Clinical Trial
Center in Peking Union Medical College Hospital. Staging of
lung cancer patients was performed according to the National
Comprehensive Cancer Network guidelines upon chest radi-
ography, bronchoscopy, brain, and thoracic computed tomog-
raphy (CT), positron emission tomography and bone scintig-
raphy. Clinical responses of first-line chemotherapy in
follow-up study were classified by CT scanning according
to the Response Evaluation Criteria in Solid Tumors.
Forty-seven lung cancer patients including 3 stage I/II,
22 stage III and 22 stage IV of 27 ADC, 7 SCC, and 13 SCLC
patients, plus 18 health donors (HD) and 13 nonmalignant
tuberculosis patients (TB) with multiple nodules in lung were
enrolled in this blinded study. Among the 47 lung cancer
patients, 41 were newly diagnosed, and another 6 were
recurrent.
Before each collection of blood samples, the first 2 ml
of blood were discarded to avoid potential epithelial cell
contamination, 7.5 ml peripheral blood was subsequently
drawn from the median cubital vein into a BD Vacutainer
tube. All blood samples were processed within 24 hours after
collection.
To avoid bias, all blood samples (including control and
patient) collection, encoding, enrichment, and result reading
were blindly performed by different personnel. Decoding and
evaluation of correlation between CTC counting and patient
clinical status were coperformed by cross blinded physicians
and research scientists.
Statistical Analysis
One way-analysis of variance and t test biostatic anal-
ysis of the results obtained from all different categories of
lung cancer patients were performed and plotted by means of
the GraphPad Prism, Version 4.0. San Diego, CA.
RESULTS
Validation of the New Enrichment Strategy
with Spiking Study
To validate the ability of our method of detecting lung
cancer cells in blood a series of blinded spiking studies were
performed using human lung cancer cell line A549. Results
show that almost all the spiked cells at different range of 5,
10, 20, 50, and 100 spiked cells can be recovered, (Figure 1)
and white blood cell (WBC) depletion is constantly main-
tained at 3–4 logs (data not shown), indicating that the
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current protocol is able to efficiently remove WBC and enrich
spiked lung cancer cells from peripheral blood, with a high
degree of accuracy.
Enrichment of CTC from Lung Cancer Patients
Eighteen HD, 13 nonmalignant TB patients, and 47
lung cancer patients including 3 stage I/II, 22 stage III and 22
stage IV of 27 ADC, 7 SCC, and 13 SCLC patients were
enrolled in this blinded study. Blood samples were collected
before chemotherapy therapy unless indicated, and subse-
quently subjected to enrichment and CTC counting. A posi-
tive patient was defined as one whose CTC count in 7.5 ml
blood was 2. Distribution of positive cells among all con-
trol groups and patients is demonstrated in Figure 2.
CTC Detection Sensitivity on Newly Diagnosed
and Recurrent Lung Cancer Patients
As shown in Figure 2 and summarized in Table 1, no
HD was positive. One nonmalignant TB patient had 2 cells in
7.5 ml blood. 67% of ADC stage I–II (2of 3), 78% ADC stage
III (7 of 9) as well as 46% ADC stage IV (5 of 11) were found
to have2 CTC in 7.5 ml blood. For SCC patients, 75% SCC
stage III (3 of 4) were positive for CTC 2. There were no
detectable CTC in 2 of SCC stage IV patients. With respect
to SCLC, 60% SCLC III (3 of 5) and 71% SCLC IV (5 of 7)
were positive. For those six nontreated yet recurrent patients,
all but one (SCC stage III) were positive for CTC detection (5
of 6 patients, 83%). The average detection sensitivity for all
histologic cancers according to stage I–II, III and IV were 67,
72, and 50%, respectively. The recurrent patients showed the
highest detection sensitivity of 83%.
Analysis of CTC Detection on Patients
Classified by Different Pathologic Types and
Stages
To evaluate the efficiency of the approach applied in
this study on the enrichment of lung cancer CTC, all of
nontreated patients including 41 newly diagnosed and 6
recurrent patients were pooled and classified into the different
pathologic types and stages.
As revealed in Figure 3, in the category of 27 ADC
patients, 67% stage I–II (2 of 3), 82% of stage III (9 of 11)
and 54% of IV (7 of 13) were found to have positive CTC
(CTC 2 cells/7.5 ml blood). Among the 2 of CTC 2 stage
I–II patients, 1 patient had CTC 5. In the total of 9 ADC
stage III CTC 2 patients, 5 patients have CTC higher than
5 cells/7.5 ml blood, which is about 56% (5 of 9). However,
in 5 of ADC IV CTC 2 patients, 43% (3 of 7) have CTC
5. In the group of 7 SCC patients, 60% (3 of 5) of SCC
stage III were found to be CTC positive, and among those
FIGURE 1. Blinded validation of the new enrichment strat-
egy by spiking study. Live human lung cancer cells A549
were labeled with 4-6-diamidino-2-phenylindole (DAPI), fol-
lowed by trypsinization and washed. The desired number of
cells ranging from 5, 10, 20, 50, to 100 (determined under
microscope or from series dilution) were spiked into 7.5 ml
blood, followed by enrichment procedure. Obtained cells
were enumerated under microscope. The plot was obtained
from an average of four separate triplicate experiments. The
doted line represents initial spiked cell number, and solid
line represents the recovered number of cells. Result shows
the number of recovered cells is almost identical to cells
spiked in the blood.
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FIGURE 2. Distribution of circulating tumor cell (CTC) en-
riched from nontreated lung cancer patients. The new en-
richment strategy was applied to isolate CTC from 47 lung
cancer patients, including 41 newly diagnosed and 6 recur-
rent patients before subjected to chemotherapy. The gray
dash line indicates 1 cell per 7.5 ml blood as the cutoff
point. A cutoff of 2 cancer cells per 7.5 ml blood was clas-
sified as positive. In 18 healthy donors (HD), only 1 had a
positive cell. In 13 of tuberculosis patients (TB), 1 patient
had 1 and another had 2 positive cells. In the group of 41
newly diagnosed patients 2 of 3 patients with stage II/II
were positive for CTC. Among 18 stage III patients, 13 sub-
jects (including 7 adenocarcinoma [ADC], 3 squamous cell
carcinoma [SCC] and 3 small cell lung cancer [SCLC]) were
found to be positive, All of the 20 stage IV patients were
positive. In the group of 6 recurrent patients, 2 stage III plus
2 stage IV ADC as well as 1 of SCLC (stage III) were positive
for CTC detection.
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subjects, 67% (2 of 3) had CTC 5. In two of SCC IV
patients, no CTC was detected.
In the category of 13 SCLC, 67% (4 of 6) SCLC stage
III and 71% (5 of 7) SCLC stage IV were noted to have
positive CTC (CTC 2). Among those, 50% of stage III and
40% of stage IV CTC positive patients were CTC 5,
respectively.
Results in Figure 3 indicate that ADC stage III had the
highest CTC 2 positive rate of 82%, followed by ADC
stage I–II (67%) and ADC stage IV (54%). In view of the
important clinical significance of CTC 5 reported on other
cancers such as BCA,7,8 we analyzed percentage of lung
cancer patients with CTC 5 among the positive patients of
CTC 2. The percentage of CTC 5 among those CTC 2
patients were 56% (III), 50% (I–II) and 43% (IV), respec-
tively. SCC III had the highest CTC 5 rate of 67% in
positive patients though its CTC 2 detection is about 60%.
In the case of SCLC, both stage III and IV patients had
similar CTC 2 detection rate of 67 to 71%, with CTC 5
of 50% (III) and 40% (IV), respectively.
Statistical Analysis of CTCave
In view of the published important clinical significance
of the number of detected CTC on breast cancer patients,
further statistical analysis was performed on both newly
diagnosed and recurrent lung cancer patients in this study to
analyze the average number of counted CTC (CTCave). As
shown in Figure 4A, ADC stages I–II, III, and IV had
CTCave value of 5, 8.5, and 2.5, respectively. SCC III had a
value of 6.5. The CTCave value of SCLC III and IV are 3.5
and 10.5, respectively. However, recurrent patients have the
highest value of 11. Similar analysis was performed on
pooled newly diagnosed patients based on different stages.
Result in Figure 4B indicates that among a total of 3 stage
1-II, 18 stage III and 20 stage IV patients, the obtained
CTCave value is 5, 7, and 7, respectively.
Correlation of CTC Enumeration and CT
Evaluation in a Follow-Up Study
A small scale of follow-up study was conducted to
evaluate a correlation of radiographic appearance (CT scan-
ning) and CTC counts in this study. As shown in Figure 5, 12
patients including 7 ADC, 2 SCC, and 3 SCLC were sub-
jected to CTC counting before and after 2 courses of first line
chemotherapy, followed by CT examination. Eight of 12
patients (patient 1–8) including 5 ADC, 2 SCC, and 1 SCLC
were classified by CT as stable disease. Among those 8
patients, 5 patients (patient 3, 4, 5, 6, and 8) dropped their
CTC count to 0, patient 4 decreased from 21 to 3, patient 2
and 7 CTC remained 0 after 2 courses of treatment. Patient 1
was noted to have an increase from 2 to 3 following therapy.
For partial response patients including 2 SCLC and 1 ADC
(patient 9–11), patient 9 CTC drops from 52 to 0, and another
2 patients had a CTC count remaining below 2. The only
patient whose CTC dramatically increased from 2 to 12 after
2 cycles of therapy was patient 12, and this patient was
thereafter confirmed to have progression of disease (PD) by
CT scanning. Clinical responses in this study were classified
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FIGURE 3. Circulating tumor cell (CTC) detection rate of
pooled nontreated lung cancer patients. All of nontreated
patients including both newly diagnosed and recurrent are
classified into stage I–II, III, and IV on each adenocarcinoma
(ADC), squamous cell carcinoma (SCC) and small cell lung
cancer (SCLC) pathologic types. Sixty-seven percent of ADC
I–II (2 of 3), 82% ADC III (9 of 11) and 54% of ADC IV (7 of
13) were positive for CTC (CTC 2 cells/7.5 ml blood). The
percentage of CTC 5 among those CTC 2 patients are
50, 56, and 43%, respectively. Among SCC patients, 60% of
stage III (3 of 5) were CTC positive with 67% (2 of 3 posi-
tive patients) of CTC 5. No CTC was detected in 2 of
SCC IV patients. In the category of SCLC, 67% (4 of 6)
and 71% (5 of 7) patients were CTC positive for stage III
and IV, and their CTC 5 rate is 50 (2 of 4) and 40% (2
of 5), respectively.
TABLE 1. Analysis of CTC Detection Sensitivity
Pathological Types n
CTC >2
Positive Patient Number %
Health donors 18 0
Tuberculosis 13 0
I–II
ADC 3 2 67
III
ADC 9 7 78
SCC 4 3 75
SCLC 5 3 60
Sensitivity 18 13 72
IV
ADC 11 5 46
SCC 2 0 0
SCLC 7 5 71
Sensitivity 20 10 50
Recurrence
Sensitivity 6 5 83
CTC, circulating tumor cell; ADC, adenocarcinoma; SCC, squamous cell carci-
noma; SCLC, small cell lung cancer, n, number.
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by CT scanning according to the Response Evaluation Crite-
ria in Solid Tumors (RECIST).
DISCUSSION
The clinical significance of CTCs is described else-
where.4,11 The method of capturing CTC from BCA patients
which is based on the expression of adhesion molecule
EpCAM on the tumor cell surface has been well estab-
lished.7,18 However, due to the heterogenic expression of
EpCAM among different pathologic types of cancer,18,23 the
ability of this tumor cell surface molecule based detection in
other cancers is unclear. In this study, instead of attempting to
directly capture CTC, we designed a strategy to enrich CTC
via depleting RBC, WBC, and serum proteins, in essence a
negative enrichment concept. Obtained lung cancer CTC
shows good morphology as shown in Figure 6.
A series of blinded validation studies performed by
spiking cultured A549 cells into blood show that this strategy
is accurate in detecting the number of cancer cells from the
blood specimens. In the validation study (Figure 1), an almost
identical number of cells could be recovered from the blood
samples. With respect to the recovery on samples where 50
and 100 cells were spiked, variation might be due to impre-
cise number of spiked cells from series dilution.
We subsequently performed further clinical validation
study on 34 NSCLC and 13 SCLC patients plus 18 HD and
13 of nonmalignant tuberculosis (TB) patients. To avoid
interference of chemotherapy on CTC enumeration, blood
was drawn from patients before they were subjected to
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FIGURE 4. Statistical analysis of circulating tumor cell
(CTC) counting. A, Newly diagnosed and recurrent patients
(all pathologic types): statistical analysis indicates the varia-
tion of the number of CTC enriched from different patho-
logic types at different stages. ADC stages I–II, III and IV
have an average counting (Mean, CTCave) of 5, 8.5, and
2.5 cells in 7.5 ml blood, respectively. Squamous cell carci-
noma (SCC) III has an CTCave value of 6.5. No detectable
CTC is observed in 2 of SCC IV patients. Regarding small cell
lung cancer (SCLC) patients, CTCave 3.5 and 10.5 are found
on SCLC III and IV, respectively. The recurrent group of pa-
tients has highest CTCave value of 11. The significance of
difference between health donors (HD) and each of patho-
logic types is denoted by (*p  0.05) and (**p  0.01). B,
Pooled newly diagnosed patients: statistical analysis on stage
I–II, III and IV patients from pooled various pathologic types
of newly diagnosed patients shows that CTCave of stage
I–II (n  2), stage III (n  13) and stage IV (n  10) is 5
(*p  0.05), 7 (***p  0.0001), and 7 (***p  0.0005),
respectively.
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FIGURE 5. Correlation of circulating tumor cell (CTC)
counting and computed tomography (CT) scanning with a
follow-up study. Correlation of CT scanning and CTC count-
ing was evaluated on a small scale of follow-up study. CTC
was enumerated from each patient before chemotherapy
started. After two courses of first line chemotherapy, patient
CTC was measured, followed by CT examination. Eight of
12 patients (patient 1–8) including 5 adenocarcinoma
(ADC), 2 squamous cell carcinoma (SCC) and 1 small cell
lung cancer (SCLC) were classified by CT as stable disease.
Among those 8 patients, 5 patients dropped their CTC to 0,
1 patient dropped from 21 to 3, 2 patients remained 0, and
in 1 patient the count increased from 2 to 3. Three patients
had a partial radiologic response: For partial response (PR)
patients (patients 9–11), one was noted to have a CTC drop
from 52 to 0, while the CTC in the other 2 patients re-
mained below 2. Only one patient was noted to have an
increasing CTC, from 2 to 12 after treatment, and this pa-
tient was confirmed to have progressive disease (PD). Clini-
cal responses are classified by CT scanning according to the
Response Evaluation Criteria in Solid Tumors (RECIST).
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chemotherapy. Among 47 lung cancer patients, there were 3
stage I–II, 22 stage III, and 22 stage IV of 27 ADC, 7 SCC,
and 13 SCLC patients. In the HD group, none of donors was
found to have CTC more than 2 in 7.5 ml blood, which is in
consistent with that previously reported by others.18 Taking
CTC  2/7.5 ml blood as a cutoff point, as shown in Table
1, newly diagnosed patients of ADC stage III and SCC III
have highest detection rate of 75 to 78%, and average detec-
tion sensitivity of stage III including ADC, SCC, and SCLC
is about 72%. Stage I–II patients have a comparable similar
detection rate of 67% though there are only three cases
examined in this study. About 50% of the average detection
sensitivity is found on stage IV patients. However, recurrent
patients are found to have highest detection sensitivity of
83%. Interestingly, it has been realized that ADC stage IV
patients have lower CTC detection sensitivity compared with
others demonstrated in the Table 1. Similar observation is
obtained when analysis is performed on the patients pooled
from both newly diagnosed and recurrent as shown in Figure
3. The reason stage IV patients did not have a higher preva-
lence of positive CTC counts is unknown.
Important clinical implication of the number of
counted CTC on BCA from various studies has been
reported.4,6,11,24,25 Five BCA CTC/7.5 ml blood is of par-
ticular clinical significance and have been taken as the
clinical cutoff point for BCA.7,8 Despite unavailable cell
number as a clinical cutoff point for lung cancer, we
statistically analyzed the number of counted lung cancer
CTC by taking BCA as an example. Results from the
analysis performed on pooled nontreated patients of newly
diagnosed and recurrent as shown in Figure 3 indicate that
among those patients with CTC 2, about 50  6% of
ADC positive patients have CTC 5; 45  5% of SCLC
are CTC 5, whereas SCC III have the percentage of 67%.
Further analysis of the mean of counted CTC (CTCave) on
separate newly diagnosed and recurrent patient in Figure
4A indicates that SCLC IV has CTCave value of 10.5 in
newly diagnosed patients, whereas recurrent patients show
the highest CTCave value around 11. Of particular interest
is the observation that recurrent lung cancer patients have
both highest detection sensitivity (83% in Table 1) and
CTCave. It has been recently reported that CTC detected
by reverse transcription polymerase chain reaction corre-
lates to recurrence of colorectal cancer.26 Results from our
study suggest the potential significant clinical utility in
terms of detecting elevated CTC with respect to monitor-
ing lung cancer relapse. Additional statistical analysis on
pooled all newly diagnosed patients classified upon stage
as shown in Figure 4B reveals the CTCave value for each
stage is 5, 7, and 7, respectively, indicating that clinically,
CTC enumeration on newly diagnosed patients with dif-
ferent stages may be significant.
Clinical impact of counting CTC during therapy for
metastatic BCA in a follow-up study were previously pub-
lished by others.6–8 In those studies, correlation between
CTC and response to chemotherapy on BCA patients and
correlation of CTC counts with local PD were observed,
indicating that CTC relates to disease status and tumor
load. To observe correlation between lung cancer CTC
enumeration and CT scanning, a small scale follow-up
study was conducted by us on 12 lung cancer patients.
Result of the blind study demonstrated in Figure 5 showed
that after 2 courses of first line chemotherapy 7 patients
were found to have a decrease in CTC counts, and another
4 patients remained stable. There was only 1 patient whose
CTC increased from 2 to 12, and this patient was subse-
quently classified by CT scanning as PD. In the present
small scale study, our observation of the correlation be-
tween CTC enumeration and CT scanning suggests that
CTC has the potential to correlate to disease status in lung
cancer.
Taken together, this report demonstrates that lung can-
cer CTC can be efficiently enriched and detected by the
approach applied in this study. The potential significant
clinical utility of detecting lung cancer CTC with respect to
monitoring recurrence and rapid evaluation of therapeutic
effects in real time are revealed in this preliminary study.
Certainly a large scale study would be necessary in the future
to further shed light on illustrating clinical utility of lung
cancer CTC.
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FIGURE 6. Visualization of lung cancer circulating tumor
cell (CTC). CTC enriched from lung cancer patient was sub-
jected to immunofluorescent (IF) staining (A) for identifica-
tion of CTC and immunohistochemical (IHC) staining (B) for
counter staining. A, Showed that CTC was specifically immu-
nostained with both anti-Cytokeratin (CK) 8/18 and anti-CK
19, but not with anti-CD45 IHC staining as revealed in (B).
Nucleus of cells were stained with 4-6-diamidino-2-phe-
nylindole (DAPI) (A). Only white blood cells (WBCs) were
found CD45 positive but CK negative as demonstrated in B.
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